These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

43 related articles for article (PubMed ID: 2177347)

  • 1. Platinum drugs in the treatment of non-small-cell lung cancer.
    Cosaert J; Quoix E
    Br J Cancer; 2002 Oct; 87(8):825-33. PubMed ID: 12373594
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quality of life in advanced non-small-cell lung cancer: results of a Southwest Oncology Group randomized trial.
    Moinpour CM; Lyons B; Grevstad PK; Lovato LC; Crowley J; Czaplicki K; Buckner ZM; Ganz PA; Kelly K; Gandara DR
    Qual Life Res; 2002 Mar; 11(2):115-26. PubMed ID: 12018735
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II study of 4'-iodo-4'-deoxydoxorubicin in non-resectable non-small-cell lung cancer.
    Sørensen JB; Stenbygaard L; Drivsholm L; Dombernowsky P; Hansen HH
    Cancer Chemother Pharmacol; 1993; 32(5):399-402. PubMed ID: 8393388
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oral verapamil with chemotherapy for advanced non-small cell lung cancer: a randomised study.
    Millward MJ; Cantwell BM; Munro NC; Robinson A; Corris PA; Harris AL
    Br J Cancer; 1993 May; 67(5):1031-5. PubMed ID: 8388231
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Women with lung cancer: impact on quality of life.
    Sarna L
    Qual Life Res; 1993 Feb; 2(1):13-22. PubMed ID: 8387854
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differences in treatment and survival rates of non-small-cell lung cancer in three regions of France.
    Grosclaude P; Galat JP; Macé-Lesech J; Roumagnac-Machelard M; Mercier M; Robillard J
    Br J Cancer; 1995 Nov; 72(5):1278-82. PubMed ID: 7577482
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quality of life measurement for patients undergoing treatment for lung cancer.
    Fergusson RJ; Cull A
    Thorax; 1991 Sep; 46(9):671-5. PubMed ID: 1948799
    [No Abstract]   [Full Text] [Related]  

  • 8. Phase II study of Edatrexate in stage III and IV non-small-cell lung cancer.
    Souhami RL; Rudd RM; Spiro SG; Allen R; Lamond P; Harper PG
    Cancer Chemother Pharmacol; 1992; 30(6):465-8. PubMed ID: 1327568
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New perspectives in lung cancer.5. New drugs in lung cancer.
    Talbot DC; Smith IE
    Thorax; 1992 Mar; 47(3):188-94. PubMed ID: 1325676
    [No Abstract]   [Full Text] [Related]  

  • 10. Vinorelbine. A review of its antitumour activity in lung cancer.
    Sørensen JB
    Drugs; 1992; 44 Suppl 4():60-5; discussion 66-9. PubMed ID: 1283851
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Recent progress in chemotherapy for advanced lung cancer].
    Negoro S; Fukuoka M
    Gan To Kagaku Ryoho; 1995 Mar; 22(4):451-60. PubMed ID: 7887637
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial.
    Paz-Ares L; de Marinis F; Dediu M; Thomas M; Pujol JL; Bidoli P; Molinier O; Sahoo TP; Laack E; Reck M; Corral J; Melemed S; John W; Chouaki N; Zimmermann AH; Visseren-Grul C; Gridelli C
    Lancet Oncol; 2012 Mar; 13(3):247-55. PubMed ID: 22341744
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Phase III studies of combined chemotherapy and radiation in locally advanced non-small-cell lung cancer and limited small-cell lung cancer].
    Kawahara M
    Gan To Kagaku Ryoho; 1995 Feb; 22(3):335-40. PubMed ID: 7880104
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chemotherapy in advanced non-small cell lung cancer.
    Splinter TA
    Eur J Cancer; 1990; 26(10):1093-9. PubMed ID: 2177347
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Efficacy and prognostic factors of 178 advanced non-small lung cancer patients undergoing different second-line chemotherapeutic regimens].
    Kong Q; Wang XY; Jiang RC; Ba Y; Li K
    Zhonghua Zhong Liu Za Zhi; 2016 Apr; 38(4):294-9. PubMed ID: 27087377
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Erlotinib and gefitinib for treating non-small cell lung cancer that has progressed following prior chemotherapy (review of NICE technology appraisals 162 and 175): a systematic review and economic evaluation.
    Greenhalgh J; Bagust A; Boland A; Dwan K; Beale S; Hockenhull J; Proudlove C; Dundar Y; Richardson M; Dickson R; Mullard A; Marshall E
    Health Technol Assess; 2015 Jun; 19(47):1-134. PubMed ID: 26134145
    [TBL] [Abstract][Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 3.